Compare NUS & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUS | IMMP |
|---|---|---|
| Founded | 1984 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.4M | 264.9M |
| IPO Year | 1996 | N/A |
| Metric | NUS | IMMP |
|---|---|---|
| Price | $10.64 | $2.56 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 404.5K | ★ 1.7M |
| Earning Date | 11-06-2025 | 02-22-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.20 | N/A |
| Revenue | ★ $1,560,391,000.00 | $3,306,742.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.12 | N/A |
| P/E Ratio | $4.81 | ★ N/A |
| Revenue Growth | N/A | ★ 31.28 |
| 52 Week Low | $5.32 | $1.32 |
| 52 Week High | $14.62 | $3.53 |
| Indicator | NUS | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 58.56 | 72.34 |
| Support Level | $9.63 | $1.67 |
| Resistance Level | $10.18 | $2.68 |
| Average True Range (ATR) | 0.31 | 0.25 |
| MACD | 0.12 | 0.09 |
| Stochastic Oscillator | 92.66 | 48.12 |
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.